Abbott Laboratories (ABT) released its Q2 2025 financial results before the market opened.
Revenue for the quarter came in at $11.14 billion, surpassing estimates of $11.07 billion. Adjusted earnings were reported at $1.26 per share, slightly above the estimated $1.25.
Compared to the same quarter last year, revenue rose by approximately 7.3%, increasing from $10.38 billion and earnings grew by about 10.5%, up from $1.14 per share a year ago.
The company revised its full-year 2025 earnings outlook to a range of $5.10 to $5.20, slightly adjusting from the prior $5.05 to $5.25 estimate, while the consensus estimate stands at $5.16.
For Q3 2025, the earnings outlook is set between $1.28 and $1.32 per share, below the estimated $1.34.
